Teva Makes Headway in European Copaxone Patent Case
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
Generic Copaxone 40 mg has been available in large parts of Europe since October 2017, and getting manufacturers to pull it from existing markets will be an uphill legal battle. Teva, however, has already managed to obtain preliminary injunction orders on the patent's basis in Belgium, Denmark, and Slovakia, where no generic version has been commercialized yet.
While in 2016, Copaxone accounted for almost a fifth of Teva's revenues, in 2018 global Copaxone sales amounted to $2.4 billion, out of $18.85 billion total revenues, largely due to the impact of generic competition. The largest drop in revenues was seen in North America, but sales in Europe had also taken a hit, and Teva forecasted the competition will continue to erode Copaxone profits in 2019.
The company will continue to defend its intellectual property regarding Copaxone 40 mg, Richard Daniell, Teva Europe's executive vice president, said in a statement Monday.